QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.50 (-3.23%)
BABA   72.31 (+1.15%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.12%)
MU   73.65 (+0.71%)
CGC   0.72 (+2.85%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.83 (+0.59%)
PFE   28.62 (-0.59%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)

ABVC BioPharma Stock Price, News & Analysis (NASDAQ:ABVC)

$1.25
-0.10 (-7.41%)
(As of 12/7/2023 ET)
Compare
Today's Range
$1.22
$1.36
50-Day Range
$0.81
$2.02
52-Week Range
$0.67
$18.70
Volume
437,472 shs
Average Volume
930,199 shs
Market Capitalization
$9.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABVC stock logo

About ABVC BioPharma Stock (NASDAQ:ABVC)

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC Stock Price History

ABVC Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
ABVC BioPharma Enters Into Global LIcensing Agreement With AiBtl
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
What's Going On With ABVC Biopharma Stock Friday?
ABVC Shares More than Triple on Licensing Deal
See More Headlines
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/03/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABVC
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-16,420,000.00
Net Margins
-1,611.23%
Pretax Margin
-1,493.78%

Debt

Sales & Book Value

Annual Sales
$970,000.00
Book Value
$0.99 per share

Miscellaneous

Free Float
4,412,000
Market Cap
$9.11 million
Optionable
Not Optionable
Beta
0.46
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Eugene Jiang (Age 37)
    Chairman & Chief Business Officer
    Comp: $200k
  • Mr. Leeds Chow (Age 34)
    CFO & Principal Accounting Officer
    Comp: $130k
  • Dr. Tsung-Shann Jiang EMBA (Age 69)
    Ph.D., Chief Scientific Officer & Director
    Comp: $200k
  • Dr. Uttam Yashwant Patil Ph.D.
    Chief Executive Officer














ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed in 2023?

ABVC BioPharma's stock was trading at $6.25 at the beginning of 2023. Since then, ABVC stock has decreased by 80.0% and is now trading at $1.25.
View the best growth stocks for 2023 here
.

Are investors shorting ABVC BioPharma?

ABVC BioPharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 87,700 shares, a decrease of 91.1% from the October 31st total of 984,400 shares. Based on an average daily volume of 2,430,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the shares of the company are sold short.
View ABVC BioPharma's Short Interest
.

When is ABVC BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our ABVC earnings forecast
.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Monday, April, 3rd. The company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($1.90) by $0.40. The firm had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.03 million. ABVC BioPharma had a negative trailing twelve-month return on equity of 348.52% and a negative net margin of 1,611.23%.

When did ABVC BioPharma's stock split?

ABVC BioPharma's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

(ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ABVC) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -